Ligand validation:6LYK

IMD: IMIDAZOLE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6LYK_IMD_A_1611	22%	70%	0.254	0.872	0.4	0.76	-	-	0	0	100%	1
6JT7_IMD_A_1531	36%	68%	0.18	0.873	0.79	0.45	-	-	0	0	100%	1
4RS3_IMD_A_413	100%	61%	0.034	0.994	0.77	0.71	-	-	0	0	100%	1
6THT_IMD_A_301	100%	89%	0.036	0.993	0.6	0.05	-	-	0	0	100%	1
9FP4_IMD_A_402	100%	74%	0.036	0.993	0.23	0.76	-	-	0	0	100%	1
5OKB_IMD_B_502	100%	75%	0.036	0.984	0.38	0.58	-	-	1	0	100%	1
6IJ1_IMD_A_402	100%	52%	0.036	0.984	0.55	1.27	-	-	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.